Drug Trial Radar · NCT05303519
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
365
Planned (sponsor's estimate)
Start
Jun 5, 2023
Primary completion
Dec 1, 2028
Study completion Dec 1, 2030
Sponsor
- Lead sponsor
- Nuvation Bio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- AnHeart Therapeutics Inc.
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized, double-blind, and placebo-controlled. The purpose of Part 3 will be to evaluate the efficacy of safusidenib in participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma who have received surgery as their only treatment. Part 3 will be an open-label single-arm cohort and will enroll participants concurrently with Part 2.
Conditions
- Glioma
- Astrocytoma, Grade IV
- IDH1-mutant Glioma
- Astrocytoma, IDH-Mutant, Grade 3
- Astrocytoma, IDH-Mutant, Grade 4
- Astrocytoma, IDH-Mutant, Grade 2
- Oligodendroglioma
- Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
Interventions
safusidenibDrug
safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.
PlaceboDrug
Placebo administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with placebo until disease progression or another reason for discontinuation occurs.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: From participants sign ICF to 30 days after last dose,average 2 years
- Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0Time frame: From randomization until the date of first documented disease progression, average 2 years
- Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months
Locations
75 sites in 9 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama · Recruiting
Mayo Clinic - Arizona
Phoenix, Arizona · Recruiting
St. Joseph's Hospital and Medical Center
Phoenix, Arizona · Recruiting
University of California San Diego
La Jolla, California · Recruiting
University of California, Los Angeles
Los Angeles, California · Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
University of California
San Francisco, California · Recruiting
University of Colorado Health Cancer Care
Aurora, Colorado · Recruiting
Yale University
New Haven, Connecticut · Recruiting
University of Florida Health
Gainesville, Florida · Recruiting
Mayo Clinic - Florida
Jacksonville, Florida · Recruiting
University of Miami Health
Miami, Florida · Recruiting
Orlando Health Cancer Institute
Orlando, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Northwestern Medicine Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois · Not yet recruiting
University of Chicago
Chicago, Illinois · Not yet recruiting
Indiana University
Indianapolis, Indiana · Recruiting
University of Kansas Medical Center
Kansas City, Kansas · Recruiting
University of Kentucky
Lexington, Kentucky · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Mayo Clinic - Rochester
Rochester, Minnesota · Recruiting
Washington University
St Louis, Missouri · Recruiting
Billings Clinic
Billings, Montana · Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey · Recruiting
NYU Langone Health
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Columbia University Medical Center
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of Rochester Medical Center
Rochester, New York · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
Oregon Health Science University
Portland, Oregon · Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
OneOncology Research Network
Nashville, Tennessee · Not yet recruiting
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.